Abbott Laboratories, Inc recalls Apolipoprotein B is an in vitro diagnostic assay for the quantitative determination of apolipoprotein B in human serum…
- Recall date
- May 16, 2018
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Recall number
- Z-1994-2019
- FDA classification
- Class II
- Brand / firm
- Abbott Laboratories, Inc
- Sold / distributed
- Distribution was nationwide, including Puerto Rico. There was government/military distribution. Foreign distribution was made to Canada, Albania, Algeria, Andorra, Argentina, Armenia, Australia, Austria, Azerbaijan, Bangladesh, Belarus, Belgium, Bolivia, Bosnia and Herzegovi, Botswana, Brazil, Brun…
Why it was recalled
An update to the Reagents and Specimen Collection and Handling/Preparation for Analysis sections of the IFU was required due to different issues with the various products.
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Apolipoprotein B is an in vitro diagnostic assay for the quantitative determination of apolipoprotein B in human serum or plasma. Antibodies to apolipoprotein B combine with apolipoprotein B in the sample to form insoluble immune complexes. The immune complexes cause an increase in light scattering (turbidity). The resulting increase in sample turbidity, measured at 604 nm, is directly proportional to the concentration of apolipoprotein B in the sample.
Get recall alerts
Free email alert whenever Abbott Laboratories, Inc has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Abbott Laboratories, Inc